MCF Advisors’s Protalix BioTherapeutics PLX Stock Holding History

MCF Advisors’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.3K	Buy	+10,000	New	+$21.2K	﹤0.01%	865

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

MCF Advisors's PLX Position: Q2 2026 in Review

MCF Advisors opened a new position in Protalix BioTherapeutics (PLX) in Q2 2026: 10,000 shares worth $23.3K. The stake represents ﹤0.01% of the portfolio and ranks #865 among its holdings.

102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

MCF Advisors held 10,000 shares of Protalix BioTherapeutics worth $23.3K as of Q2 2026.
Protalix BioTherapeutics was a new MCF Advisors position in Q2 2026.
Protalix BioTherapeutics made up ﹤0.01% of MCF Advisors's portfolio in Q2 2026, its #865 holding.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on MCF Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.